Drug intelligence / Profile preview

RJ018

Development stage: Preclinical
Lead developer: Risen
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

RJ018 is a preclinical-stage small interfering RNA (siRNA) therapeutic candidate being developed by Risen Shanghai Medical Technology (also known as Risen Pharma) for the treatment of metabolic diseases. As an siRNA molecule, RJ018 is designed to leverage the RNA interference (RNAi) pathway to specifically silence the expression of a target gene involved in metabolic dysfunction. While the specific molecular target of RJ018 remains undisclosed, the program is part of Risen Pharma's broader focus on developing liver-targeted RNA therapeutics for chronic conditions.

Beyond the preview

Go deeper on RJ018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ018.

Explore the full profile